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Background: In PLATO, ticagrelor compared with clopidogrel reduced the primary composite endpoint of CV death, MI (excluding silent MI), or 
stroke in patients with acute coronary syndromes. We explored the effect of ticagrelor on MI, including different types of MI and the impact of event 
adjudication.
methods: A central clinical events committee (CEC) prospectively defined, systematically identified, and adjudicated MI events.
results: Overall, 18,624 patients were enrolled in PLATO; 1,097 (Kaplan-Meier % at 1 year: 6.4%) patients had at least one MI identified by 
the CEC (504 [5.9%] ticagrelor; 593 [6.9%] clopidogrel; HR 0.84; 95% CI [0.75[[Unable to Display Character: &#8211;]]0.95]; P = 0.005), and 
975 (5.7%) patients had at least one MI identified by the site investigators (459 [5.3%] ticagrelor; 516 [6.0%] clopidogrel; HR 0.88; 95% CI 
[0.78[[Unable to Display Character: &#8211;]]1.00]; P = 0.052). Table 1 shows the MI types reported by the CEC and the site investigators and 
treatment comparisons. Of the 1,097 MIs reported by the CEC, 681 (62%) were also reported by site investigators, and 416 (38%) were not (205 in 
ticagrelor group, 211 in clopidogrel group).
conclusions: In patients with acute coronary syndromes, ticagrelor significantly reduced MI compared with clopidogrel, with consistent results 
across most MI subtypes. CEC procedures identified more MI endpoints than reported by site investigators. 
Table 1. Treatment Effect by Type of Myocardial Infarction
Type of Myocardial Infarction Total Ticagrelor Clopidogrel Ticagrelor vs. Clopidogrel HR (95% CI)
Classified by CECa
Any 1,107 508 599 0.840 (0.746-0.945)
Non-silent 1,097 504 593 0.842 (0.748-0.948)
Silent 11 5 6 0.829 (0.253-2.716)
Non-Procedure Related 812 366 446 0.812 (0.707-0.933)
Procedure-related 304 144 160 0.895 (0.715-1.122)
PCI-related 223 99 124 0.794 (0.609-1.034)
CABG-related 82 45 37 1.212 (0.784-1.872)
Associated with stent thrombosis 172 69 103 0.666 (0.491-0.903)
Any non-silent MI 1,097 504 593
STEMI 275 117 158 0.736 (0.579-0.935)
NSTEMI 760 356 404 0.875 (0.758-1.008)
Not evaluable 92 40 52 0.765 (0.507-1.155)
Q wave 77 37 40 0.921 (0.589-1.440)
Non Q wave 708 333 375 0.881 (0.761-1.022)
Q wave not evaluable 368 160 208 0.763 (0.621-0.938)
Classified by investigatora
Any MI 975 459 516 0.883 (0.779-1.001)
STEMI 352 156 196 0.791 (0.641-0.976)
NSTEMI 594 287 307 0.929 (0.791-1.091)
Other 60 29 31 0.931 (0.561-1.545)
aIncludes first event of each type per patient. 
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